EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2008/08/01
-
Journal
-
Indian UGC (journal)
-
Refrences50
-
Citations479
-
Marko Babjuk
-
Willem Oosterlinck
-
Richard Sylvester
-
Eero Kaasinen
-
Andreas Böhle
-
Juan Palou-Redorta
Cite
Babjuk, Marko, et al. “EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder”. European Urology, vol. 54, no. 2, 2008, pp. 303-14, https://doi.org/10.1016/j.eururo.2008.04.051.
Babjuk, M., Oosterlinck, W., Sylvester, R., Kaasinen, E., Böhle, A., & Palou-Redorta, J. (2008). EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder. European Urology, 54(2), 303-314. https://doi.org/10.1016/j.eururo.2008.04.051
Babjuk, Marko, Willem Oosterlinck, Richard Sylvester, Eero Kaasinen, Andreas Böhle, and Juan Palou-Redorta. “EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder”. European Urology 54, no. 2 (2008): 303-14. https://doi.org/10.1016/j.eururo.2008.04.051.
Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder. European Urology. 2008;54(2):303-14.
Journal Categories
Medicine
Internal medicine
Specialties of internal medicine
Diseases of the genitourinary system
Urology
Medicine
Medicine (General)
You May Also Like
- Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer
- Could inflammation be a key component in the progression of benign prostatic hyperplasia?
- Renal cell carcinoma: etiology, incidence and epidemiology
- How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study
- The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder | Urology |
| 122 | 2005 |
| Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers | Urology |
| 285 | 2005 |
| The Schedule and Duration of Intravesical Chemotherapy in Patients with Non–Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials | European Urology |
| 120 | 2008 |
| Treatment Paradigm Shift May Improve Survival of Patients With High Risk Superficial Bladder Cancer | Journal of Urology |
| 102 | 2007 |
| Clinically Relevant Reduction in Risk of Recurrence of Superficial Bladder Cancer Using 5-Aminolevulinic Acid-Induced Fluorescence Diagnosis: 8-Year Results of Prospective Randomized Study | Urology |
| 176 | 2007 |
Refrences Analysis
The category
Medicine: Medicine (General) 25
is the most frequently represented among the references in this article. It primarily includes studies from European Urology and Urology. The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| On relevant features for the recurrence prediction of urothelial carcinoma of the bladder | International Journal of Medical Informatics |
| 2024 | |
Comparison of narrow band imaging versus white light imaging in detecting non muscle invasive bladder cancer | Urologia Journal |
| 2024 | |
Long‐term prevention of bladder cancer progression by alpha1‐oleate alone or in combination with chemotherapy | International Journal of Cancer |
| 2023 | |
| Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial | European Urology |
| 22 | 2023 |
| Editorial Comment on Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non‐muscle invasive bladder cancer: A multi‐institutional collaborative study | International Journal of Urology |
| 2023 |
Citations Analysis
The category
Medicine: Medicine (General) 348
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Intravesical Electromotive Drug Administration® (EMDA) with Mitomycin-C for non-muscle invasive bladder cancer and was published in 2008. The most recent citation comes from a 2024 study titled On relevant features for the recurrence prediction of urothelial carcinoma of the bladder. This article reached its peak citation in 2010, with 104 citations. It has been cited in 169 different journals, 17% of which are open access. Among related journals, the European Urology cited this research the most, with 49 citations. The chart below illustrates the annual citation trends for this article.